Breaking Down the enVista Voluntary Recall
Cathleen McCabe, MD, and Brent Saunders, chairman and CEO of Bausch + Lomb, join the podcast to break down details of the recent voluntary recall of enVista Aspire, enVista Envy, and certain enVista monofocal IOLs. Hosts Blake Williamson, MD, MPH, and Gary Wörtz, MD, invite discussion on how the Ba…
Bausch + Lomb aims to shake up contact lenses with deal off the table: EXCLUSIVE
Bausch + Lomb said this month it had explored taking the company private with a third-party buyer. No deal was reached as a consortium of private equity firms TPG and Blackstone reportedly backed out. Bausch + Lomb (BLCO) said it would not pursue a transaction at this time. But it reiterated a view…
Bausch + Lomb’s John Ferris on Making Science Approachable, Reducing Friction, and Winning in the AI Commerce Era
In this episode of BRAVE COMMERCE, hosts Rachel Tipograph and Sarah Hofstetter sit down with John Ferris, President, Consumer at Bausch + Lomb, to discuss how modern consumer behavior is rewriting the rules for legacy brands. John shares how his team is tackling a core challenge in eye health: cons…
Pharmaceutical Executive Daily: Thomas Appio Named Interim CEO of Bausch + Lomb
Bausch + Lomb names Thomas Appio interim CEO as Brent Saunders departs, a Pharm Exec interview explores how AI is reshaping entry-level apprenticeship in professional services, and a LogiPharma 2026 conversation makes the case against waiting for perfect data to deploy AI in pharma supply chains.
One-Year Clinical and Real-World Outcomes with the TENEO Excimer
In this episode, Drs. Waring and Chu share clinical insights and real-world experience from the first year of using the Teneo 317 excimer laser for correcting myopia and myopic astigmatism. As the first excimer platform to receive FDA approval in over 15 years, the Teneo 317 introduces modern perfo…
SOTS 2nd Hour: Your Earnings Playbook - from Big Tech to Healthcare, Plus Anthropic Fundraise Details 4/30/26
From big tech earnings to the Fed's decision to hold rates steady...
Carl Quintanilla, Sara Eisen, and David Faber broke down what investors should know this hour - and what it means for the markets - with an all-star cast including Janus Henderson's Global Macro Investing head and one of the stre…
Why AI Will Challenge Treasury Professionals Who Fail to Adapt
AI is reshaping how treasury professionals analyse information, manage workloads and make decisions.
In this episode, Manoj Panda, Vice President and Treasurer at Bausch + Lomb, draws on more than 20 years of global finance and treasury leadership experience to explain why the greatest risk may not…
The Current State of Multifocal and Trifocal IOL Technologies
Blake Williamson, MD, MPH, and Gary Wörtz, MD, invite William Plauché, MD, to review a presentation he recently delivered at the Caribbean Eye Meeting about his experience with PanOptix (Alcon), enVista Envy (Bausch + Lomb), and Tecnis Odyssey (Johnson & Johnson Vision) IOLs. The presentation compa…
Study Examines Semaglutide and Wet AMD Risk
An international study examines the link between a popular weight loss medication and wet AMD risk; Heidelberg receives FDA clearance for a Spectralis software upgrade; and Bausch + Lomb launches its latest over-the-counter dry eye relief product in the US.
Learn more about your ad choices. Visit…
150 - Ocular/Ophthalmic Drug Delivery, Intravitreal Administration, Glaucoma, WetAMD, Vision, Range and Presence with Maysaa Attar
On this episode, I was joined by Maysaa Attar, Senior Vice President of R&D at Bausch + Lomb. On this episode, Maysaa discusses:
00:00 Welcome to Episode 150!
03:00 Challenges and Innovations in Ocular Drug Delivery
09:30 Understanding Intravitreal Injections
13:26 Regulatory Considerations for Oc…
Podcast 搜尋引擎
您可以使用我們的網站按人物、地點或主題搜尋3,827,863Podcast 和196,301,102單集。
If I have seen further than others, it is by listening to podcasts and standing upon the shoulders of
giants.
‐ Isaac "Llamacorn" Newton
